1 citations,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
November 2024 in “Journal of Family Medicine and Primary Care” 5 Alpha Reductase Inhibitors (ARIs) are commonly used for conditions like benign prostatic hypertrophy, androgenetic alopecia, and hirsutism. Although they are generally safe, ARIs can cause side effects that may persist even after stopping the medication. This review aims to inform primary care physicians about these common side effects, emphasizing the importance of considering ARIs as a potential cause of new symptoms in patients. This awareness is crucial for accurate diagnosis and management of adverse drug reactions related to ARIs.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
June 2024 in “Reviews on Recent Clinical Trials” Finasteride and dutasteride may cause metabolic issues like liver disease and diabetes.
June 2024 in “Drug and therapeutics bulletin” Finasteride can cause depression, suicidal thoughts, and lasting psychiatric and sexual issues.
June 2024 in “Research Square (Research Square)” Finasteride overdose can cause acute pancreatitis.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
December 2023 in “Magna Scientia Advanced Research and Reviews” The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
December 2023 in “Alzheimer's & Dementia” Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
November 2023 in “Acta scientific pharmaceutical sciences” Different methods accurately measure Finasteride in medicines and body fluids.
September 2023 in “Journal of the American Academy of Dermatology” GoodRx.com helps find the cheapest options for finasteride, a medication not often covered by insurance.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
December 2021 in “Innovation in aging” Frailer men have a higher risk of worsening prostate problems and serious health events needing hospital care.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
Pumpkin roots contain compounds like Alpha-spinasterol, squalene, and palmitic acid, which may have health benefits like reducing depression, treating certain cancers, and having antibacterial properties.
April 2020 in “The Journal of Urology” Big chain pharmacies in Pennsylvania charge significantly more for generic BPH medications than independent pharmacies, but independent pharmacies have more regional price variation.
March 2020 in “StatPearls” Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.
Endurance exercise may help BPH by lowering hormones and inflammation.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
January 2018 in “Surgical and Cosmetic Dermatology” 5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
February 2017 in “The Journal of urology/The journal of urology” Castration significantly reduces prostate size and BPH symptoms.
January 2017 in “The journal of sexual medicine” Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.